Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Dirix(GZA Ziekenhuizen Campus Sint-Augustinus), Erika Hamilton(Sarah Cannon), Leisha A. Emens(Johns Hopkins University), Andres Forero‐Torres(Kirklin Clinic), Marc E. Lippman(Georgetown University), Anja von Heydebreck(Merck (Germany)), Petros Nikolinakos(University Cancer and Blood Center), Kevin M. Chin(Merck (Germany)), Robert A. Somer(Cooper Medical School of Rowan University), Borys Hrinczenko(Michigan State University), István Takács(Semmelweis University), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Martin Šmakal(Nemocnice Na Pleši), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Jayne S. Gurtler(Littoral Research Group (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), H. Grote(Merck KGaA, Darmstadt (Germany)), W. Jeff Edenfield(Prisma Health)
Cited by 761
Related Papers
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Targeting HER2-positive breast cancer: advances and future directions
|Nature Reviews Drug Discovery|2022|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
|Cancer Immunology Research|2015|814